Unlock The Disruptive Potential: Analytical Development & Characterization For mRNA
Source: MilliporeSigma
The proven efficacy of mRNA technology as a vaccine against SARS-CoV-2 has driven rapid development, scalability, and flexibility. Its disruptive potential extends beyond prophylactic vaccines to treatments for diseases, such as cancer and immune disorders. MilliporeSigma's assay packages provide the product and process knowledge needed to develop a Quality Target Product Profile (QTPP) and identify the Critical Quality Attributes (CQAs) to unchain the disruptive potential of your mRNA therapy. Download the flyer to learn more about how MilliporeSigma can help you meet your mRNA product’s specific needs.
access the Brochure!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more